BiotechTube

CTX-009 + Paclitaxel

Phase 2/3Active
0 views this week 0 watching💤 Quiet
Interest: 36/100
36
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Biliary Tract Cancer

Conditions

Biliary Tract Cancer, Cholangiocarcinoma, Gall Bladder Cancer, Ampullary Cancer

Trial Timeline

Jan 9, 2023 → Dec 1, 2025

NCT ID
NCT05506943

About CTX-009 + Paclitaxel

CTX-009 + Paclitaxel is a phase 2/3 stage product being developed by Compass Therapeutics for Biliary Tract Cancer. The current trial status is active. This product is registered under clinical trial identifier NCT05506943. Target conditions include Biliary Tract Cancer, Cholangiocarcinoma, Gall Bladder Cancer.

What happened to similar drugs?

2 of 20 similar drugs in Biliary Tract Cancer were approved

Approved (2) Terminated (0) Active (18)
✅Tranexamic acid + Standard of CarePfizerApproved
✅abataceptBristol Myers SquibbApproved
🔄Rilvegostomig + Durvalumab + Gemcitabine/CisplatinAstraZenecaPhase 3
🔄durvalumabAstraZenecaPhase 3
🔄Rilvegostomig + Placebo + Capecitabine + Gemcitabine/Cisplatin + S-1 [Tegafur/Oteracil/gimeracil]AstraZenecaPhase 3
🔄Gemcitabine + Cisplatin + Durvalumab + Trastuzumab deruxtecan + RilvegostomigAstraZenecaPhase 3
🔄Durvalumab + Gemcitabine monotherapy + Gemcitabine + cisplatin + Gemcitabine + oxaliplatin + Gemcitabine + carboplatin + Gemcitabine + cisplatin + S-1 + Gemcitabine + S-1 + Gemcitabine + cisplatin + albumin-bound paclitaxelAstraZenecaPhase 3

Hype Score Breakdown

Clinical
15
Activity
12
Company
9
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT05506943Phase 2/3Active

Competing Products

20 competing products in Biliary Tract Cancer

See all competitors
ProductCompanyStageHype Score
mFOLFOX regimen + MitazalimabAlligator Bioscience ABPhase 2/3
35
Trastuzumab deruxtecanDaiichi SankyoPhase 2
39
Trastuzumab deruxtecanDaiichi SankyoPhase 2
42
Camrelizumab and Apatinib Plus GPSun PharmaceuticalPhase 1/2
28
Recaticimab and Adebrelimab + GP chemotherapySun PharmaceuticalPhase 2
42
Fenofibrate IDD-P (Insoluble Drug Delivery-Micro Particle)ShionogiPhase 2
35
E6011 + PlaceboEisaiPhase 2
27
LenvatinibEisaiPhase 2
35
gemcitabine + cisplatinEli LillyPhase 2
35
gemcitabine + cisplatinEli LillyPhase 2
35
Ramucirumab + Merestinib + Cisplatin + Gemcitabine + Placebo Oral + Placebo IVEli LillyPhase 2
39
Baricitinib + PlaceboEli LillyPhase 2
27
AbemaciclibEli LillyPhase 2
27
SHR-A1811Jiangsu Hengrui MedicinePhase 2
42
SHR1258Jiangsu Hengrui MedicinePhase 2
27
ApatinibJiangsu Hengrui MedicinePhase 2
31
SHR-1210+GEMOXJiangsu Hengrui MedicinePhase 2
35
Rilvegostomig + Durvalumab + Gemcitabine/CisplatinAstraZenecaPhase 3
47
Durvalumab + Gemcitabine + CisplatinAstraZenecaPre-clinical
33
durvalumabAstraZenecaPhase 3
40